跳至主要内容
临床试验/NCT03818087
NCT03818087进行中(未招募)不适用

Elevate! : Improving Outcomes for Older Patients With Breast Cancer:a Longitudinal Cohort and Patient Engagement Study

Dana-Farber Cancer Institute4 个研究点 分布在 1 个国家目标入组 253 人开始时间: 2019年2月19日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
253
试验地点
4
主要终点
Treatment patterns by age and other characteristics

研究概览

简要总结

This study is focused on understanding how the investigators can improve upon breast cancer and health outcomes for older participants with breast cancer.

详细描述

This study is focused on understanding how the investigators can improve upon breast cancer and health outcomes for older participants with breast cancer, a group of participants who often have low risk cancers, but who may do worse than younger participants with the same kind of cancers. Researchers want to better understand the experiences, barriers, and changes in physical function older participants with breast cancer have.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
70 Years 至 —(Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age 70 or older at the time of diagnosis (as indicated by the date of breast biopsy)
  • No more than 67 patients (1/3) will be aged 70-74, with the remaining patients on study ages 75 or older
  • Any gender is eligible
  • Invasive, non-metastatic breast cancer at diagnosis
  • Those with prior diagnoses of pre-invasive (DCIS) or invasive breast cancer are eligible as long as their current diagnosis is felt by the treating provider to represent a NEW non-metastatic primary invasive breast cancer (e.g. someone with a nodal recurrence from prior disease are not eligible but those with a new contralateral breast cancer 3 years after a first breast cancer would be eligible)
  • Any breast cancer subtype is allowed
  • Breast cancer-diagnosing biopsy within 90 days of enrollment
  • Receiving or will receive medical oncology care (+/- surgical and radiation oncology treatments) at the participating center: DFCI/satellites and affiliate sites
  • Patients must be able to understand, speak, and read English or assign a designated caregiver/proxy for the duration of the study who understands, speaks, and reads English and who is willing to assist with filling out the survey components which do not have a validated, translated version. This is because the surveys are not readily available in multiple languages as a whole, although some components (such as the Geriatric Assessment and PROs are readily available in multiple languages).
  • If a patient scores 11 or higher on the baseline Orientation-Memory-Concentration Test done at baseline (Appendix E), a proxy/designee must then be assigned to help the patient fill out the questionnaires for the duration of the study in order to participate. The treating provider will also be notified about the cognitive impairment.
  • Ability to provide informed consent

排除标准

  • Pathological or clinical stage 0, IV disease
  • Those with nodal or metastatic recurrences at the time of enrollment
  • Unable to speak and read English AND no designee who speaks and reads English, as above
  • Unable to provide informed consent

结局指标

主要结局

Treatment patterns by age and other characteristics

时间窗: 7 years

We will examine treatment receipt and patterns by subtype of disease

Adjuvant treatment recommendations

时间窗: 7 years

Report treatment recommendations made to patients enrolled on the cohort

Adherence to hormonal therapy

时间窗: 7 years

We will survey patients on adherence

Barriers to treatment and adherence

时间窗: 7 years

We will survey patients on the reasons for adherence and poor adherence

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rachel Freedman, MD, MPH

Primary Investigator

Dana-Farber Cancer Institute

研究点 (4)

Loading locations...

相似试验